Alentis Therapeutics
PrivateLast Round
Series D
Nov 12, 2024
Est. Valuation
$2B
Total Funding Raised
$365.9M
Company Overview
Alentis Therapeutics is a biopharmaceutical company focused on developing innovative treatments for cancer and fibrotic diseases, utilizing advanced technologies to address conditions such as Claudin-1 positive tumors and liver fibrosis.
Sector
Healthcare & Life Sciences
Verticals
Biotechnology, Drug Discovery, Clinical Trials, Precision Medicine
Business Model
B2B
Customer Profile
Revenue Share, Government Contracts
AI Layer
Non-AI
Keywords
Historical Pricing
Historical view of private secondary pricing and transaction trends.
Alentis Therapeutics Comps
Public and private peers based on sector, stage, and business model.
Alentis Therapeutics Funding Rounds
Historical fundraising activity
| Round | Date | Amount Raised | Valuation | Investors | Sources |
|---|---|---|---|---|---|
| Series D | Nov 12, 2024 | ||||
| Series C | Apr 13, 2023 | ||||
| Series B | Jun 15, 2021 | ||||
| Series A | Apr 30, 2019 |
Key People
Founding team and executive leadership
Alentis Therapeutics Investors
Notable investors and investment history
| Investor | Rounds |
|---|---|
| Longitude Capital | Series D |
| BioMedPartners | Series A, Series B |
| RA Capital Management | Series D, Series C |
| Heartland Healthcare Capital | Series D |
| Morningside Ventures | Series B |
| Bpifrance | Series B, Series C, Series A, Series D |
| OrbiMed | Series D |
Market signals
Structured signals derived from secondary market and firmographic data.
- Nov 12, 2025
Dr. Venugopal joins the executive leadership team.
- Nov 12, 2025
Mr. Yoon has joined the executive leadership team.
Alentis Therapeutics Filings
SEC and related filings with document metadata.
| Typed | Date | Amount Offered | Amount Sold | Filling | Pages | Download |
|---|---|---|---|---|---|---|
Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation |
Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation |
Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation |
Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation |
Frequently Asked Questions
Common questions about Alentis Therapeutics's valuation, stock price, and market status.
